|

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

RECRUITINGPhase 1Sponsored by Qualigen Theraputics, Inc.
Actively Recruiting
PhasePhase 1
SponsorQualigen Theraputics, Inc.
Started2023-11-01
Est. completion2025-12
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations4 sites
View on ClinicalTrials.gov →

NCT06086522

Summary

Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patient.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with histologically confirmed locally advanced or metastatic solid carcinomas, who have had tumor progression after receiving all standard of care therapies or for which there is no approved therapy 2. Evaluable or measurable disease by RECIST 1.1

Exclusion Criteria:

\-

Conditions2

CancerSolid Tumor

Locations4 sites

Arizona

1 site
HonorHealth
Scottsdale, Arizona, 85251
Andrew Islas833-354-6667

Connecticut

1 site
Yale
New Haven, Connecticut, 06520
Patricia LoRusso, DO

Michigan

1 site
START Midwest
Grand Rapids, Michigan, 49546
Abigail VanKirk616-389-1824

Texas

1 site
MD Anderson Cancer Center
Houston, Texas, 77002
Jordi Rodon, MD

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.